Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Hum Exp Toxicol ; 35(6): 644-53, 2016 Jun.
Article in English | MEDLINE | ID: mdl-26264742

ABSTRACT

BACKGROUND: Ischemic heart disease is the leading cause of death in postmenopausal women. The expression of caveolin, a membrane protein and a negative regulator of nitric oxide (NO), increases after menopause. The present study was designed to determine the effect of daidzein (DDZ), a phytoestrogen in attenuated cardioprotective effect of ischemic preconditioning (IPC) in ovariectomized rat heart. METHODS: Heart was isolated from ovariectomized rat and mounted on Langendorff's apparatus, subjected to 30 min ischemia and 120 min reperfusion. IPC was mediated by four cycles of 5 min ischemia and 5 min reperfusion. The infarct size was estimated using triphenyltetrazolium chloride stain, and coronary effluent was analyzed for lactate dehydrogenase and creatine kinase MB (CK-MB) release to assess the degree of myocardial injury. The release of NO was estimated indirectly by measuring the release of nitrite in coronary effluent. RESULTS: IPC-induced cardioprotection was significantly attenuated in ovariectomized rats as compared to normal rats, which was restored by treatment of DDZ, a caveolin inhibitor (0.2 mg/kg subcutaneously) for 1 week. However, this observed cardioprotection was significantly attenuated by perfusion of l-nitroarginine methyl ester, an endothelial nitric oxide synthase (eNOS) inhibitor (100 µM/L) and glibenclamide, an adenosine triphosphate-sensitive potassium ion channel blocker (10 µM/L) alone or in combination, noted in terms of increase in myocardial infarct size, release of LDH and CK-MB, and also decrease in the release of NO. CONCLUSION: Thus, it is suggested that DDZ restores the attenuated cardioprotective effect in ovariectomized rat heart, which may be due to downregulation of caveolin and subsequent increase in the activity of eNOS.


Subject(s)
Heart/physiology , Ischemic Preconditioning, Myocardial , Myocardial Infarction/metabolism , Myocardial Infarction/prevention & control , Ovariectomy , Animals , Caveolin 1/antagonists & inhibitors , Caveolin 1/metabolism , Creatine Kinase, MB Form/metabolism , Disease Models, Animal , Female , Heart/drug effects , In Vitro Techniques , Isoflavones/pharmacology , L-Lactate Dehydrogenase/metabolism , Nitrites/metabolism , Phytoestrogens/pharmacology , Rats, Wistar
SELECTION OF CITATIONS
SEARCH DETAIL
...